ICOS - 下一代免疫療法 - 競爭情形與市場預測:2035年
ICOS-Next Generation Immunotherapy - Competitive Landscape and Market Forecast - 2035
|出版商||DelveInsight Business Research LLP||商品編碼||954174|
|出版日期||按訂單生產||內容資訊||英文 75 Pages
|ICOS - 下一代免疫療法 - 競爭情形與市場預測:2035年 ICOS-Next Generation Immunotherapy - Competitive Landscape and Market Forecast - 2035|
|出版日期: 按訂單生產||內容資訊: 英文 75 Pages||
ICOS - 下一代免疫療法市場規模，從2022年到2035年的預測期間內預計以大幅度的年複合成長率發展，預計2035年生成86億7600萬美元。美國是七個主要的ICOS市場之一，預計2035年佔約49.48％的佔有率。預計各疾病中，NSCLC至2035年構成60.19％的大幅市場佔有率。還有各疾病的市場規模預計至2023年成為86億7600萬美元。
本報告提供全球主要7個市場的ICOS - 下一代免疫療法市場相關調查，市場概要，病理學，目前市場趨勢，技術創新情勢，產品的檢討，市場成長的影響要素，及主要7個市場等相關詳細資訊。
DelveInsight's 'ICOS-Next Generation Immunotherapy-Competitive Landscape and Market Forecast-2035' report delivers an in-depth understanding of the ICOS as well as the market trends of ICOS-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The report provides the upcoming drugs, market share of this target by indications, forecasted market size of ICOS-Next Generation Immunotherapy from 2022 to 2035 segmented by seven major markets. The report also covers the current scenario, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Study Period: 2022-2035.
Cancer immunotherapy (CI) is rapidly advancing and can now be considered to be the "fifth pillar" of cancer therapy, joining the ranks of surgery, cytotoxic chemotherapy, radiation, and targeted therapy. The CI which has sparked the most interest involves antibodies to inhibitory immune checkpoint molecules.
Inducible co-stimulator (ICOS) is a specific T cell co-stimulatory molecule of the CD28/CTLA-4 family mainly expressed by CD4 T cells. It is a co-stimulator of proliferation and cytokine production by these cells. Its levels are upregulated in activated T lymphocytes, especially after the use of anti-CTLA4 therapies, and its expression is considered as a biomarker to indicate that anti-CTLA4 agents are binding its target.
Interestingly, ICOS appears to be a less potent pathway compared to other forms of immunotherapy mainly because of a predominant CD4 expression. However, its use with other approaches, particularly CTLA4 blockade can lead to a potent synergistic effect as a result of an increase in the expression of ICOS after anti-CTLA4 therapy.
The rapid development of immuno-oncology (I-O) therapies for multiple types of cancer has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer.
ICOS has significant homology with the other two family members, costimulatory CD28 and coinhibitory receptor CTLA-4. Furthermore, T cells costimulated by ICOS can achieve levels of activation comparable to CD28. ICOS signals induce the production of a wide spectrum of cytokines by CD4+ T helper (Th) cells, CD4+ forkhead box P3 (FoxP3+) Tregs and CD8+ cytotoxic T lymphocytes (CTL) that function to enhance their proliferation and direct memory cell development.
ICOS was also shown to be an important element in the persistence of CD4+ chimeric Ag receptor (CAR) T cells, a form of passive immunotherapy that is currently in use in clinical trials, particularly for hematological malignancies.
The ICOS/ICOSL pathway can also modulate antitumor Teff responses by specifically modulating Th1 and CTL activities. Early phase clinical trials testing ICOS agonist antibodies in patients with advanced solid tumors have shown good safety profiles and promising antitumor activities, particularly when the compounds are given as a combination with anti-PD-1 agents (pembrolizumab and nivolumab).
In human cancer, ICOS expression on FoxP3+ Tregs is well established. In comparison to their counterparts in the periphery, Treg tumor-infiltrating lymphocytes (TIL) express increased levels of FoxP3 and several other markers including CTLA-4, glucocorticoid-induced TNFR family-related gene and ICOS in addition to secreting higher levels of IL-10 and TGFB.
This segment of the ICOS-Next Generation Immunotherapy report encloses the detailed analysis of late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the indication-specific clinical trial details, expressive pharmacological actions, agreements and collaborations, approval and awards, advantages and disadvantages of each included drug, and the latest news and press releases.
The major key players such as GlaxoSmithKline, Bristol-Myers Squibb, Jounce Therapeutics, Xencor, Kymab, etc, and others will significantly increase the market during the forecast period (2022-2035).
The expected launch of emerging therapies, such as GSK3359609, Vopratelimab, KY1044, BMS-986226, XmAb23104, and other treatments, would lead to a significant increase in the market size during the forecast period (2022-2035).
GSK3359609, an inducible T cell co-stimulatory (ICOS) agonist antibody is designed to selectively enhance T cell function. After the administration, anti-ICOS agonist antibody GSK3359609 targets and binds to ICOS expressed on tumor-infiltrating CD4-positive T cells. This stimulates ICOS-positive T-cell proliferation which enhances cytotoxic T-lymphocyte (CTL) survival and increases CTL-mediated immune responses against tumor cells. ICOS, a T-cell specific, CD28-superfamily costimulatory molecule, and immune checkpoint protein is normally expressed on certain activated T cells and plays a key role in the proliferation and activation of T cells.
Vopratelimab (also known as JTX-2011) is a clinical-stage monoclonal antibody that binds and activates ICOS, the Inducible T cell CO-Stimulator which is a protein present on the surface of certain T cells found in many solid tumors. The drug is currently in phase II (EMERGE) clinical trial in combination with ipilimumab in patients previously treated with PD-1/PD-L1 inhibitor therapies. The product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in many solid tumors.
KY1044 is a human monoclonal IgG1 that selectively binds to inducible T cell co-stimulator (ICOS) which is a protein expressed at high levels on immunosuppressive regulatory T cells and lower levels on effector T cells. This can be designed to exert antitumor activity through preferential depletion of intra-tumoral regulatory T cells and stimulation (agonism) of ICOS-positive effector T cells. The drug can also improve the ratio of intra-tumoral effector T cells to regulatory T cells which promotes an antitumor immune response.
BMS-986226 is an agonistic monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ICOS agonist monoclonal antibody BMS-986226 targets and binds to ICOS expressed on certain T cells. This stimulates ICOS-mediated signaling, induces proliferation of ICOS-positive T cells, enhances cytotoxic T lymphocyte (CTL) survival and augments the CTL-mediated immune response against tumor cells. ICOS is a T-cell-specific, CD28-superfamily co-stimulatory molecule, and immune checkpoint protein.
XmAb23104 (PD-1 × ICOS) is a bispecific antibody that simultaneously targets PD-1, an immune checkpoint receptor, and ICOS, an immune co-stimulatory receptor. It is designed to promote tumor-selective T-cell activation. The drug is a bispecific Fc domain that serves as the scaffold for two antigen-binding domains and confers long circulating half-life, stability, and ease of manufacture. The company's XmAb bispecific Fc domains have been engineered to eliminate Fc gamma receptor (FcγR) binding, with the intent to prevent activation and/or depletion of T cells via engagement by FcγR-expressing cells.
The ICOS-Next Generation Immunotherapy market outlook helps to cultivate a detailed comprehension of the historical, current and forecasted market trends by analyzing the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of ICOS-Next Generation Immunotherapy market trend of each late-stage pipeline therapy by evaluating their impact based on the annual cost of treatment, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear picture of the market at first sight.
According to DelveInsight, the ICOS-Next Generation Immunotherapy market is expected to generate USD 8,676 Million in the year 2035 with a significant CAGR in the forecast period (2022-2035).
To keep up with current market trends, we take KOLs and SME's opinion working for third-generation immunotherapies in various indications through primary research to fill the data gaps and validate our secondary research. Their opinion helps us to understand and verify current and emerging therapies treatment patterns or current market trends. It will also support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the ICOS-Next Generation Immunotherapy market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the availability of the data.